Parallel MapReduce: Maximizing Cloud Resource Utilization and Performance Improvement Using Parallel Execution Strategies

Table 3

Information of the disease-causing genomic variants used in the experiment.

Experiment 1
Case study	Genome variant	Experiment details
1	SP1	A disrupted SP1 binding site in the LDL-R promoter that leads to familial hypercholesterolemia
2	TCF7L2	A cancer risk variant in a MYC enhancer weakens a TCF7L2 binding site
3	GATA1	A gained GATA1 binding site that disrupts the original globin cluster promoters
4	GATA4	A lost GATA4 binding site in the BCL-2 promoter, potentially playing a role in ovarian granulosa cell tumors
5	RFX3	Loss of two potential RFX3 binding sites leads to abnormal cortical development
6	GABPA	Gained GABP-α binding sites in the TERT promoter, which are linked to several types of aggressive cancer